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Abstract Pitavastatin is the newest member of the HMG-CoA reductase inhibitor family and is approved as
adjunctive therapy to diet to reduce elevated levels of total cholesterol, low-density lipoprotein (LDL)
cholesterol, apolipoprotein (Apo) B, and triglycerides and to increase levels of high-density lipoprotein
(HDL) cholesterol in adult patients with primary hyperlipidemia or mixed dyslipidemia. Pitavastatin un-
dergoes minimal metabolism by cytochrome P450 (CYP) enzymes and, therefore, has a low propensity for
drug-drug interactions with drugs metabolized by CYP enzymes or the CYP3A4 substrate grapefruit juice.
In clinical trials, pitavastatin potently and consistently reduced serum levels of total, LDL, and non-HDL
cholesterol, and triglycerides in patients with primary hypercholesterolemia where diet and other non-
pharmacological measures were inadequate. Mean reductions from baseline in serum total and LDL cho-
lesterol and triglyceride levels were 21–32%, 30–45%, and 10–30%, respectively. Moreover, a consistent
trend towards increased HDL cholesterol levels of 3–10% was seen. Long-term extension studies show that
the beneficial effects of pitavastatin are maintained for up to 2 years. Pitavastatin produces reductions from
baseline in serum total and LDL cholesterol levels to a similar extent to those seen with the potent agent
atorvastatin and to a greater extent than those seen with simvastatin or pravastatin.
In the majority of other studies comparing pitavastatin and atorvastatin, no significant differences in the
favorable effects on lipid parameters were seen, although pitavastatin was consistently associated with
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trends towards increased HDL cholesterol levels. Pitavastatin also produces beneficial effects on lipids in
patients with type 2 diabetes mellitus and metabolic syndrome without deleterious effects on markers of
glucose metabolism, such as fasting blood glucose levels or proportion of glycosylated hemoglobin. Pita-
vastatin appears to exert a number of beneficial effects on patients at risk of cardiovascular events in-
dependent of lipid lowering. In the JAPAN-ACS (Japan Assessment of Pitavastatin and Atorvastatin in
Acute Coronary Syndrome) study, pitavastatin was non-inferior to atorvastatin at reducing plaque volume
in patients with ACS undergoing percutaneous coronary intervention. Further beneficial effects, including
favorable effects on the size and composition of atherosclerotic plaques, improvements in cardiovascular
function, and improvements in markers of inflammation, oxidative stress, and renal function, have been
demonstrated in a number of small studies. Pitavastatin is generally well tolerated in hyperlipidemic patients
with or without type 2 diabetes, with the most common treatment-related adverse events being musculo-
skeletal or gastrointestinal in nature. Increases in plasma creatine kinase levels were seen in <5% of
pitavastatin recipients and the incidence of myopathy or rhabdomyolysis was extremely low. In summary,
pitavastatin, the latest addition to the statin family, produces potent and consistent beneficial effects on
lipids, is well tolerated, and has a favorable pharmacokinetic profile. The combination of a potent decrease
in total and LDL cholesterol levels and increase in HDL cholesterol levels suggest that pitavastatin may
produce substantial cardiovascular protection.
Cardiovascular disease (CVD) is the leading cause of death
in men and women in the majority of European countries,
causing over 4.3million deaths per year.[1] TheWHOMONICA
(Multinational Monitoring of Trends and Determinants in
Caiovascular Disease) study showed great variation in the
prevalence of cholesterol levels of ‡6.5mmol/L, ranging from
8% to 53% in men and from 15% to 40% in women.[2] Mean
serum cholesterol levels across Europe ranged from 4.5 to
6.5mmol/L in men and from 4.5 to 6.2mmol/L in women.[3]
The INTERHEART study (A Study of Risk Factors for First
Myocardial Infarction in 52 Countries) estimated that indi-
viduals with dyslipidemia are three times more likely to have a
myocardial infarction than those with normal lipid levels, and
that abnormal lipid levels are the cause of 45% of myocardial
infarctions in Western Europe.[4]
The relationship between serum cholesterol levels and
cardiovascular risk is well defined.[5] A 10% reduction in plasma
total cholesterol levels is associated with a 25% reduction in the
5-year incidence of CVD, and a 1mmol/L reduction in low-
density lipoprotein (LDL) cholesterol level is associated with a
20% reduction in cardiovascular events.[6] A strong relationship
also exists between low high-density lipoprotein (HDL) cho-
lesterol levels and cardiovascular risk, whereas a high trigly-
ceride level indicates the need to investigate the cluster of risk
factors termed ‘metabolic syndrome.’[5]
HMG-CoA reductase inhibitors (statins) are the drugs of
choice in patients with dyslipidemia.[5] In addition to reducing
hyperlipidemia, this class of agents has been shown to reduce
cardiovascular events, mortality, and the need for coronary
revascularization.[5] Furthermore, intensive statin therapy ap-
pears to halt progression or induce regression of coronary
atherosclerosis[7,8] and further reduce the incidence of major
vascular events.[9]
Pitavastatin is the newest member of the HMG-CoA re-
ductase inhibitor class of agents and is approved as adjunctive
therapy to diet to reduce elevated levels of total cholesterol,
LDL cholesterol, apolipoprotein (Apo) B, and triglycerides,
and to increase HDL cholesterol levels in adult patients with
primary hyperlipidemia or mixed dyslipidemia.[10] This review
discusses the pharmacology, efficacy, and tolerability of pita-
vastatin in these indications. Data were identified using a
search performed on MEDLINE, and clinical trials of pita-
vastatin in humans published between 1 January 2000 and
19 October 2010 were included. Additional data are also dis-
cussed at the discretion of the author.
1. Pharmacodynamic Profile
1.1 Mechanism of Action
Pitavastatin is a synthetic statin that competitively inhibits
HMG-CoA reductase, thereby inhibiting hepatic cholesterol
synthesis and improving lipid profiles.[10] The drug inhibits
HMG-CoA reductase with a 50% inhibitory concentration
(IC50) of 6.8 nmol/L,which is 2.4-fold higher than that observed
with simvastatin and approximately 6.8-fold higher than that
observed with pravastatin.[11] Inhibition of cholesterol synthesis
from radiolabeled acetic acid in cultured human hepatoma cells
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by pitavastatin occurred with an IC50 of 5.8 nmol/L, which is
2.9- and 5.7-fold higher than that observed with simvastatin
and atorvastatin, respectively.[12] Inhibition of sterol synthesis
in rat liver occurred with a dose that produces a 50% effective
response (ED50) of 0.13mg/kg and is three times stronger than
simvastatin in the same animal.[13]
Induction of LDL receptor messenger RNA (mRNA)
by statins may reduce plasma LDL cholesterol levels. In
in vitro studies pitavastatin has been shown to increase
LDL receptor mRNA,[12] LDL binding to the LDL receptor
and internalization into the cells,[14] and degradation of Apo
B.[15] Relative to atorvastatin and simvastatin, pitavastatin
also showed greater induction of LDL cholesterol receptor
expression[12] and superior Apo AI secretion-promoting
effects.[16]
1.2 Other Effects
Recent evidence suggests that statins may have beneficial
effects on vascular function over and above those produced by
cholesterol lowering alone, often termed ‘pleiotropic’ effects,
and in vitro and in vivo studies suggest that pitavastatin also
exhibits these effects. Anti-inflammatory effects observed with
pitavastatin in in vitro studies include inhibition of C-reactive
protein (CRP)-induced interleukin-8 production by endothelial
cells,[17] stimulation of monocyte chemoattractant protein-1,[18]
and inhibition of the expression of pentraxin 3 (PTX3).[19]
Pitavastatin inhibits plasminogen activator inhibitor-1 (PAI-1)
and tissue factor,[20,21] and induces tissue plasminogen activator
and thrombomodulin,[20-22] processes that are likely to exert
beneficial effects on atherothrombotic events. In a rabbit model
of hyperlipidemia, pitavastatin 0.5mg/kg/day administered for
16 weeks was associated with a reduction in the progression
of aortic atherosclerosis.[23] Pitavastatin improved the compo-
sition of vulnerable plaques to assist plaque stabilization by
increasing collagen deposition and decreasing macrophage
infiltration.[23] Pitavastatin has been shown to reduce the gen-
eration of reactive oxygen species,[24] improve endothelial
function,[25] increase nitric oxide production,[26] inhibit cell
adhesion,[18] attenuate smooth muscle cell contraction,[27] en-
hance angiogenesis,[28] and promote Apo AI production.[16]
Even at low doses, pitavastatin inhibited human coronary ar-
tery smooth muscle cell proliferation to a greater extent than
atorvastatin, simvastatin, fluvastatin, rosuvastatin, and pra-
vastatin.[29] In in vitro studies, pitavastatin inhibited adipocyte
differentiation via inhibition of peroxisome proliferator-
activated receptor-g expression and activation of preadipocyte
factor-1.[30]
2. Pharmacokinetic Profile
2.1 Absorption and Distribution
In humans, pitavastatin achieves maximum plasma con-
centrations (Cmax) about 1 hour after oral administration, with
an absorption rate of 80% and an absolute bioavailability of
pitavastatin oral solution of 51% (administration with a fat
meal decreases Cmax, but does not affect the pitavastatin area
under the plasma concentration-time curve [AUC]).[31] Pita-
vastatin is selectively distributed to the liver, with drug con-
centrations in rat liver shown to be 54-fold higher than those
seen in plasma.[32] There are no clinically relevant effects of
food on the pharmacokinetic profile of pitavastatin.[33]
2.2 Metabolism and Excretion
Pitavastatin undergoes minimal cytochrome P450 (CYP)
metabolism in the liver; the drug enters the enterohepatic
circulation, which in turn prolongs its elimination half-life
(t½) to approximately 11–12 hours.
[32-34] Since pitavastatin is
minimally metabolized by the CYP isoenzymes, it has a low
propensity for drug-drug interactions and shows minimal
interaction with grapefruit juice (a CYP3A4 substrate).[35,36]
However, caution and/or dose reductions are recommended
when pitavastatin is co-administered with erythromycin (which
results in a 2.8-fold increase in pitavastatin AUC and a 3.6-fold
increase in Cmax), lopinavir/ritonavir, rifampicin (rifampin),
fibric acid derivatives (e.g., fenofibric acid, gemfibrozil), niacin,
and warfarin.[10]
Like other statins, the uptake of pitavastatin in the liver is
understood to be mediated by the organic anion transporter
protein (OATP) 2;[37,38] thus, exposure to pitavastatin is in-
creased when it is co-administered with OATP2 inhibitors.
When cyclosporine, anOATP1B1 inhibitor, was co-administered
with pitavastatin, a 5-fold increase in the pitavastatin AUC
from time zero to 24 hours (AUC24) was observed.
[39]
OATP1B1, which is encoded by the SLCOB1 gene, is also in-
volved in the uptake of pitavastatin in the liver. Various
pharmacokinetic studies have shown that single nucleotide
polymorphisms in this gene significantly alter the pharmaco-
kinetics of pitavastatin in healthy volunteers.[40-44]
2.3 Special Patient Populations
Patients with mild to moderate hepatic impairment experi-
ence an increase in the plasma concentration of, and exposure
to, pitavastatin. In patients with mild (Child-Pugh A) or
moderate (Child-Pugh B) hepatic impairment, the pitavastatin
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Cmax was 1.2-fold and 2.5-fold, respectively, greater than ob-
served in healthy volunteers; the respective values for AUC
extrapolated to infinity (AUC1) were 1.3-fold and 3.5-fold
higher.[45] In healthy volunteers and patients with mild or
moderate hepatic impairment, mean pitavastatin t½ values
were 10, 9, and 14 hours, respectively.[45]
Patientswith renal impairment also experiencemarked increases
inpitavastatin exposure.TheAUC1was79%and86%higher than
that seen in healthy volunteers and in patients with moderate renal
impairment (glomerular filtration rate [GFR] 30–59mL/min/
1.73m2) and end-stage renal disease undergoing hemodialysis,
respectively.[10] The effect of mild or severe renal impairment on
pitavastatin pharmacokinetics has not been studied.
There were no clinically significant differences in the phar-
macokinetic profile of pitavastatin between elderly and non-
elderly individuals.[46] The pitavastatin Cmax and AUC were
10% and 30%, respectively, higher in young compared with old
(aged ‡65 years) healthy volunteers.[10]
3. Lipid-Lowering Effects
3.1 In Patients with Dyslipidemia
The lipid-lowering effect of pitavastatin in patients with
dyslipidemia has been investigated in nine large studies of be-
tween 8 and 52 weeks’ duration (table I).[47-55] The majority
were randomized, open-label, multicenter studies. However,
three studies were double-blind,[47,50,52] one study contained
a single arm,[48] and one study was performed at a single
center.[53] Three long-term follow-up studies[58-60] and one post-
marketing surveillance study[61,62] are also available. Patients in
the studies had primary hypercholesterolemia,[47-54] hyper-
lipidemia,[55] or combined dyslipidemia.[47,50] Patients received
pitavastatin 1–4mg daily and efficacy was compared with
pravastatin 10mg daily,[52] simvastatin 10–20mg daily,[50,51]
and atorvastatin 10–20mg daily.[47,49,53-55] Where stated, the
primary endpoints of studies were change from baseline in
multiple lipid parameters (total cholesterol, LDL cholesterol,
and triglyceride levels),[52] LDL cholesterol levels,[47,50,51] or
non-HDL cholesterol levels,[54] or the proportion of patients
achieving the LDL cholesterol goal.[49] The lipid-lowering ef-
fects of pitavastatin have also been reported in small studies or
as a secondary endpoint in studies, but these will not be dis-
cussed further in this section.[63-69]
Pitavastatin consistently produces significant reductions
from baseline in serum levels of total, LDL, and non-HDL
cholesterol. In trials of up to 52 weeks’ duration, pitavastatin
decreased total cholesterol levels by 21.0–32.4% and LDL
cholesterol levels by 30.3–44.6% compared with baseline levels
(table I).[47-55] Where measured, pitavastatin was associated
with reductions from baseline in non-HDL cholesterol levels of
34.7–41.1%.[47,50,54] LDL cholesterol target levels were ach-
ieved by 56.8–93.9% of individuals when using National Cho-
lesterol Education Program (NCEP)Adult Treatment Panel III
criteria[47,49-51,53] and 56.8–78.5% using European Athero-
sclerosis Society (EAS) criteria.[47,50]
Pitavastatin also produces significant reductions from
baseline in serum triglyceride levels and a trend towards in-
creasedHDL cholesterol levels. In studies, pitavastatin reduced
serum triglyceride levels by 9.9–29.8%[47,49-55] and increased
serum HDL cholesterol levels by 2.6–8.9%,[47-55] although the
changes were not always statistically significant (table I). Pit-
avastatin is associated with favorable effects on a number of
other lipid parameters, including significant increases from
baseline in Apo AI (5.6–7.2%)[47,50,52] and Apo AII (4.2%)
levels,[52] and significant decreases in the levels ofApoB (-29.7%
to -35.3),[47,50,52] Apo CII (-15.7%),[52] Apo CIII (-9.5%),[52]
Apo E (-22.9%),[52] oxidized LDL (-22.3% and -25.5%, with
pitavastatin 2mg and 4mg, respectively),[47] and remnant-like
particle (RLP) cholesterol (-22.8%).[48]
Long-term extension studies of clinical trials show that pita-
vastatin is efficacious for up to 2 years’ duration.[59,60] In an
open-label extension to the study by Ose et al.[60] in which
patients who had previously received pitavastatin, atorvastatin,
or simvastatin received pitavastatin 4mg daily, the proportion
of patients achieving NCEP and EAS LDL cholesterol targets
at 52 weeks was 74.0% and 73.5%, respectively. An extension to
a small open-label study showed that decreases in levels of total
and LDL cholesterol and triglycerides were stable over
104 weeks. Reductions in other lipid parameters, such as Apo B
levels, were also maintained.[59]
Pitavastatin produces similar improvements in lipid para-
meters to commonly used statins. Reductions from baseline in
serum LDL, total, or non-HDL cholesterol and triglyceride
levels were generally similar to those seen with equivalent doses
of atorvastatin (table I).[47,49,53-55] For example, similar reduc-
tions frombaseline in serumLDL cholesterol levels were seen in
patients receiving daily doses of pitavastatin 2mg and ator-
vastatin 10mg, and pitavastatin 4mg and atorvastatin 20mg,
with non-inferiority demonstrated between the comparators
(figure 1a). Moreover, there was no significant difference be-
tween comparators in the reduction of other lipid parameters
and the proportion of patients achieving lipid target levels
(figure 1a and b). However, in two trials, atorvastatin pro-
duced significantly greater reductions from baseline in levels
of triglycerides (-21% vs -11%; p< 0.05),[55] total cholesterol
96 Da Silva
ª 2011 Adis Data Information BV. All rights reserved. Am J Cardiovasc Drugs 2011; 11 (2)
(-32.3% vs -27.6%; p= 0.005),[53] and LDL cholesterol (-45.8%
vs -37.4%; p < 0.001).[53] Reductions from baseline in serum
lipid levels with pitavastatin were generally greater than those
seen with simvastatin or pravastatin.[50-52] For example, in the
trial by Ose et al.,[50] pitavastatin 2mg daily was associated with
a significantly greater reduction from baseline in total (-27.9%
vs -25.4%), LDL (-39.0% vs -35.0%), and non-HDL (-35.8%
vs -32.3%) cholesterol levels compared with simvastatin 20mg
daily (all p< 0.05). Pitavastatin 2mg daily produced sig-
nificantly greater reductions from baseline in LDL (-37.6% vs
-18.4%) and total (-28.0% vs -13.8%) cholesterol and trigly-
ceride (-23.3% vs 20.2%) levels compared with pravastatin
10mg daily in a 12-week study (all p< 0.05).[52]
The LIVES (Livalo Effectiveness and Safety) study was a
2-year, single-arm, uncontrolled, observational, post-market-
ing study conducted in almost 21 000 patients with hyper-
cholesterolemia or familial hypercholesterolemia designed to
assess the safety and efficacy of pitavastatin in the ‘real-world’
setting.[61] A significant reduction from baseline in the level of
LDL cholesterol (112.5 vs 164.8mg/dL; p < 0.001) was seen,
and 66.5–88.2% of primary prevention and 50.3% of secondary
prevention patients achieved Japan Atherosclerosis Society
Table I. Effect of pitavastatin on lipid parameters in patients with primary hypercholesterolemia, hyperlipidemia, or combined dyslipidemia in clinical studies
of up to 52 weeks’ duration[47-55]
Study and year
(design; duration)
No. of patients Drug and dose
(mg/day)
Changes in lipid levels from baseline values (%) Patients achieving
LDL-C goal (%)
LDL-C HDL-C non-HDL-C TC TG
Saito et al. 2002[52]
(r, db, mc; 12wk)
125 PIT 2 -37.6**- +8.9 NR -28.0**- -23.3*- 75a
111 PRA 10 -18.4** +9.8 NR -13.8** -20.2* 36a
Park et al. 2005[51]
(r, op, mc; 8wk)
49 PIT 2 -38.2 +8.3 NR -26.9 -29.8 93.9b
46 SIM 10 -39.4 +3.6 NR -28.5 -17.4 91.3b
Yoshitomi et al. 2006[55]
(op, mc; 12wk)
70 PIT 1 -38* +3 NR -28* -11 NR
67 ATO 10 -41* +7* NR -29* -21*- NR
Lee et al. 2007[49]
(r, op, mc; 8wk)
110 PIT 2 -42.9 +7.1 NR -28.2 -9.9 92.7b
112 ATO 10 -44.1 +6.7 NR -29.6 -11.0 92.0b
Koshiyama et al. 2008[48]
(mc; 52wk)
178 PIT 1-2 -30.3c +2.6c NR -21.0c NR NR
Yokote et al. 2008[54]
(r, op, mc; 12wk)
101 PIT 2 -42.6*** +3.2* -39.0***# -29.7*** -17.3*** NR
103 ATO 10 -44.1*** +1.7 -40.3*** -31.1*** -10.7** NR
Budinski et al. 2009[47]
(r, db, mc; 12wk)
316 PIT 2 -37.9## +4.0 -34.7 -27.7 -14.1 56.8b/56.8d
300 PIT 4 -44.6## +5.0 -41.1 -32.4 -19.0 77.9b/78.5d
102 ATO 10 -37.8 +3.0 -35.2 -28.1 -17.7 65.7b/59.8d
103 ATO 20 -43.5 +2.5 -40.6 -32.7 -22.3 70.6b/76.5d
Ose et al. 2009[50]
(r, db, mc; 12wk)
315 PIT 2 -39.0--### +6.0 -35.8-- -27.9-- -15.9 70.0b/59.6d
323 PIT 4 -44.0### +6.2 -40.5 -31.5 -16.8 79.6b/75.2d
108 SIM 20 -35.0 +5.5 -32.3 -25.4 -15.6 64.5b/48.6d
111 SIM 40 -42.8 +6.8 -39.4 -30.5 -16.1 78.2b/75.5d
Sansanayudh et al. 2010[53]
(r, op, sc; 8wk)
50 PIT 1 -37.4*** +2.8 NR -27.6*** -10.4*** 74.0b
50 ATO 10 -45.8***- -0.4 NR -32.3***- -7.1*** 84.0b
a Serum LDL-C level <140mg/dL.
b National Cholesterol Education Program Adult Treatment Panel III criteria.[56]
c Significant change vs baseline, p-value not stated.
d European Atherosclerosis Society criteria.[57]
ATO= atorvastatin; db =double-blind; HDL-C= high-density lipoprotein cholesterol; LDL-C= low-density lipoprotein cholesterol; mc=multicenter; NR= not
reported;op = open-label;PIT =pitavastatin;PRA= pravastatin; r= randomized; sc= single-center;SIM= simvastatin;TC = total cholesterol; TG= triglycerides;
wk=weeks; * p <0.05, ** p <0.01, *** p < 0.001 vs baseline; - p < 0.05 vs comparator; -- p < 0.05 vs SIM 20; # non-inferiority to ATO 10 demonstrated; ## PIT 2
demonstrated non-inferiority to ATO 10; PIT 4 demonstrated non-inferiority to ATO 20; ### PIT 4 demonstrated equivalence to SIM 40.
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Fig. 1. Effect of pitavastatin or atorvastatin on (a) lipid parameters and (b) the proportion of patients achieving target lipid levels according to National
Cholesterol Education Program (NCEP) or European Atherosclerosis Society (EAS) criteria in a prospective, randomized, double-blind, multicenter study in
patients with primary hypercholesterolemia or combined dyslipidemia.[47] HDL=high-density lipoprotein; LDL= low-density lipoprotein; NI = non-inferiority
demonstrated.
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guideline-recommended LDL cholesterol targets.[61] A signif-
icant reduction in triglyceride level (139.7 vs 165.8mg/dL;
p < 0.001) and increase in HDL cholesterol level (60.5 vs
59.5mg/dL; p < 0.001) was also reported.[61]
3.2 In Diabetic Patients
The efficacy of pitavastatin in patients with type 2 diabetes
mellitus has been studied in nine clinical trials of up to 52 weeks’
duration (table II).[70-79] The trials were generally open-label
and performed at a single center; one study was crossover in
design,[72] two were randomized,[72,75] and one was a retro-
spective analysis.[78] Patients had type 2 diabetes or glucose
intolerance and hyperlipidemia.
Pitavastatin produced significant reductions from baseline
in total and LDL cholesterol, and triglyceride levels in patients
with type 2 diabetes (table II). Reductions from baseline in
serum LDL cholesterol levels were between -17.5% and
-41.1%[70-78] and for total cholesterol levels were between
-12.1% and -27.1%.[70,73,74,76,78] In one study, pitavastatin was
associated with a 31.1% decrease in serum non-HDL choles-
terol levels.[75] Pitavastatin also produced decreases in trigly-
ceride levels of between -6.2% and -28.7%.[71,73-78] Increases
from baseline in plasma HDL cholesterol levels were also seen
in themajority of trials and ranged from +1.7% to +12.5%.[71-78]
The efficacy of pitavastatin (n = 28) was compared with
atorvastatin (n = 25) in a small subgroup of patients with met-
abolic syndrome.[54] The change from baseline in LDL choles-
terol levels was significantly greater in patients receiving
pitavastatin compared with atorvastatin recipients (-45.8% vs
-39.1%; p= 0.0495), although total cholesterol and non-HDL
cholesterol levels were reduced to a similar extent. Pitavastatin








Change in blood glucose parameters
from baseline values (%)




HbA1c LDL-C HDL-C TC TG
Sone et al. 2002[76]
(mc; 8wk)
33 PIT 2 +6.3 NR -36.1*** +9.7* -25.2*** -28.7*
Kawai et al. 2005[71]
(mc; 8 wk)
79 PIT 1–2 +0.9 +0.3 -36.9*** +3.1 NR -9.9***
Inami et al. 2007[70]
(sc; 6mo)
65 non-diabetic PIT 2 NR NR -39.9*** NR -28.7*** NR
52 diabetic PIT 2 NR NR -36.4*** NR -26.3*** NR
Tokuno et al. 2007[77]
(op, sc; 3mo)
NR PIT 1 +8.4 0.0 -26.9*** +1.7 NR -22.3*
NR FEN 100 -11.9 0.0 -2.2 +12.2** NR -49.1***
Monden et al. 2008[72]
(r, op, co, sc; 12wk)
20 PIT 2 NR NR -33 +4.1 NR NR
20 ROS 2.5 NR NR -42-- +7.7 NR NR
Sasaki et al. 2008[75]
(r, op, mc; 52wk)
88 PIT 2 +3.8 +5.5 -33.0 +8.2- NR -7.1
85 ATO 10 +9.8 +3.9 -40.1-- +2.9 NR -14.6
Yamakawa et al. 2008[78]
(ret, mc; 3mo)
95 PIT 2 -3.0 -1.4 -17.5 +1.8 -12.0*** -11.7
99 ATO 10 +6.0 +5.7*** -28.4*** +1.8 -21.3*** -17.9
85 PRA (NR) NR 0.0 -16.1*** +3.6 -10.6*** -1.4
Motomura et al. 2009[73]
(op, mc; 6mo)
65 PIT 2 +1.5 +4.4 -41.1*** +4.5* -27.1*** -6.2*
Nomura et al. 2009[74]
(r, op, sc; 6mo)
64 PIT 2 NR 0.0 -36.1***¥ +12.5** -24.0***¥ -13.6*
55 EPA 1800 NR 0.0 -10.9** +4.7 -11.8** -19.0***#
72 PIT 2+EPA 1800 NR -3.1 -39.1***¥ +15.2*** -27.1***¥ -28.6***#
ATO= atorvastatin; co= crossover; EPA=eicosapentaenoic acid; FEN= fenofibrate; HbA1c= proportion of glycosylated hemoglobin; HDL-C= high-density
lipoprotein cholesterol; LDL-C= low-density lipoprotein cholesterol;mc=multicentre;NR= not reported; op = open-label; PIT= pitavastatin; PRA= pravastatin;
r= randomized; ret = retrospective; ROS= rosuvastatin; sc= single centre; TC = total cholesterol; TG= triglycerides; wk=weeks; * p< 0.05, ** p < 0.01,
*** p <0.001 vs baseline; - p< 0.05, -- p < 0.01 vs comparator; # p < 0.05 vs PIT; ¥ p <0.05 vs EPA.
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was associated with significant reductions in serum triglyceride
levels and increases in HDL cholesterol levels from baseline,
whereas atorvastatin was not.[54]
Pitavastatin also produced favorable effects on other lipid
parameters, including reductions in the levels of RLP choles-
terol (-30.9%; p < 0.001),[76] Apo B (-23.5% and -28.2%),[75,77]
Apo E (-17.8%),[75] small dense LDL cholesterol (-32.4%;
p < 0.0001),[77] large buoyant LDL cholesterol (-26.1%;
p < 0.0001),[77] and increases in adiponectin (+28.4%;
p < 0.001)[70] and Apo A1 (+4.9% and +5.1%)[75,77] levels com-
pared with baseline. In one study, serum adiponectin levels
remained unchanged at study end.[72] A significant increase in
mean LDL size and LDL1 subfraction plus a decrease in LDL4
subfraction was seen in another study.[76]
Importantly, pitavastatin did not affect glycemic control.
Although increases from baseline in fasting plasma glucose le-
vels and the proportion of glycosylated hemoglobin (HbA1c)
were seen in the majority of studies, these changes were small
and generally not statistically significant (table II).[71,73-78] Al-
terations in antihyperglycemic agents were generally not per-
mitted during the study period.
3.3 In Other Patient Groups
Pitavastatin produces favorable effects on lipid levels in
elderly patients and those with chronic kidney disease (CKD).
In a study reported as an abstract, 962 elderly patients (aged
‡65 years) with primary hypercholesterolemia or combined
dyslipidemia were randomized to treatment with pitavastatin 1,
2, or 4mg daily or pravastatin 10, 20, or 40mg daily for
12 weeks followed by pitavastatin 2mg daily titrated to 4mg
daily after 8 weeks and continued for 60 weeks.[80] In the ran-
domized phase, patients receiving pitavastatin experienced re-
ductions in LDL cholesterol levels of 31–44% compared with
22–34% seen in pravastatin recipients.[80] The NCEP LDL
cholesterol target was achieved in 83–91% of pitavastatin and
65–88% of pravastatin recipients. After patients entered the
pitavastatin phase, 92% achieved NCEP targets after 8 weeks,
and at 60 weeks, 99% and 70% of patients receiving pitavastatin
2mg or 4mg daily achieved the NCEP target, respectively.[80]
The overall reduction in triglycerides levels was 20% and the
level of HDL cholesterol rose by 9.6%.
In a small study in Japanese patients with dyslipidemia and
stage I or II CKD, pitavastatin 2mg daily led to significant
reductions from baseline in levels of total (-27.9%) and LDL
(-39.8%) cholesterol and triglycerides (-12.6%), plus an in-
crease in HDL cholesterol levels (+5.6%) [all p < 0.001 vs
baseline].[81] The addition of the cholesterol absorption in-
hibitor ezetimibe further enhanced the lipid-lowering efficacy
of pitavastatin, suggesting a potential future combination
strategy. The reductions from baseline in total (-36.7%) and
LDL (-51.0%) cholesterol and triglyceride (-20.9%) levels were
all significantly greater than those seen with pitavastatin
monotherapy (all p< 0.05).[81]
4. Other Effects
4.1 Effect on Atherosclerosis
Pitavastatin significantly improved atherosclerosis compared
with dietary and lifestyle advice in patients with hyper-
cholesterolemia in small trials of 6–7 months’ duration.[82,83] In
one study, 32 patients with hypercholesterolemia and atrial fi-
brillation undergoing transesophageal echocardiography were
randomized to treatment with pitavastatin 1–2mg daily or
diet.[82] Patients in the diet group received nutritional and life-
style advice; both groups were reassessed after 7 months. Pit-
avastatin was associated with significantly greater reductions
in levels of total and LDL cholesterol and triglycerides compared
with the diet group.[82] Moreover, patients receiving pitavastatin
experienced a significantly greater reduction in corrected in-
tegrated backscatter (c-IBS) and intimal media thickness (IMT)
of the arterial media (-12.9% vs +8.7% and -11.7% vs +6.3%,
respectively; both p< 0.001). In the intimal plaque, pitavastatin
recipients experienced a significantly greater increase in c-IBS
(+32.4 vs +19.0%; p< 0.01) and decrease in IMT (-10.8% vs
+8.3%; p< 0.001) compared with patients receiving diet alone. In
a second study, 82 patients undergoing intravascular ultrasound
(IVUS)-guided percutaneous coronary intervention (PCI) were
retrospectively assigned to a low-fat diet plus pitavastatin 2mg
daily administered within 48 hours of PCI group or a low-fat diet
alone group.[83] The group that received pitavastatin had sig-
nificantly greater reductions in total and LDL cholesterol levels
compared with the diet alone group. Plaque volume index (PVI)
was significantly reduced in patients receiving pitavastatin com-
pared with the diet group (-10.6% vs +8.1%; p< 0.001).[83] Fur-
thermore, reductions in PVI correlated significantly with the
follow-up (r= 0.500) and change in LDL cholesterol level
(r= 0.0479) [both p< 0.001].
Regression of coronary plaque volume with pitavastatin was
similar to that seenwith atorvastatin in patients with ACS.[84,85]
In the multicenter, randomized JAPAN-ACS (Japan Assess-
ment of Pitavastatin and Atorvastatin in Acute Coronary
Syndrome) study, 307 patients with ACS undergoing IVUS-
guided PCI were treated with pitavastatin 4mg daily or ator-
vastatin 20mg daily for between 8 and 12 months.[84] A similar
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mean percentage decrease in plaque volume in patients receiving
pitavastatin or atorvastatin was seen (-16.9% vs -18.1%;
p = 0.05 compared with baseline for both with no significant
difference between groups), demonstrating non-inferiority be-
tween the two drugs.[84] A smaller short-term study comparing
the two drugs suggested that pitavastatin may be more effective
in reducing fibrofatty plaque composition.[85]
4.2 Effect on Inflammation and Oxidative Stress
Pitavastatin was associated with significant reductions from
baseline in levels of high-sensitivity CRP (hs-CRP) in patients
with primary hypercholesterolemia or combined dyslipidemia
with or without type 2 diabetes or ACS in studies of up to
12 months’ duration.[48-50,68,72,73,84,86,87] In a study byMotomura
et al.,[73] 65 Japanesepatientswith type 2diabetes and serumLDL
cholesterol levels ‡120mg/dL, triglyceride levels <400mg/dL,
and HbA1c <9.0% were treated with pitavastatin 2mg daily for
6 months. hs-CRP levels were significantly reduced from baseline
at 6 months and although they correlated significantly with age,
they were not associated with changes in lipid parameters.[73]
Mixed findings with regard to hs-CRP levels have been ob-
served in comparative trials with other statins. Pitavastatin
2mg or 4mg daily was associated with similar reductions in hs-
CRP levels to simvastatin 20mg or 40mg daily in a 12-week
study in patients with hypercholesterolemia or mixed dyslipid-
emia.[60] hs-CRP levels reduced to a similar extent in patients
with hypercholesterolemia receiving pitavastatin 2mg daily or
atorvastatin 10mg daily in a second study.[49] However, rosu-
vastatin 2.5mg daily produced significant reductions in
hs-CRP levels from baseline in patients with type 2 diabetes
whereas pitavastatin 2mg daily did not.[72]
In a number of small studies, pitavastatin has been associated
with significant reductions from baseline in serum levels of tu-
mor-necrosis factor-a in patients with ACS,[87] PAI-1 in patients
with type 2 diabetes,[72] PTX3,[68] and matrix metalloproteinases
2 and3[59] in patientswith hypercholesterolemia. Pitavastatin also
produced beneficial effects on markers of bone turnover, in-
cluding calcium and N-terminal telopeptide of type I collagen
in a 3-month study.[65] A number of markers of oxidative
stress have shown significant improvement with pitavastatin
treatment, including lectin-like oxidized LDL cholesterol
ligands,[66] 8-hydroxy-20-deoxyguanosine (8-OHdG),[81,88,89]
and malondialdehyde-modified (MDA) LDL.[88]
4.3 Effect on Cardiovascular Function
Pitavastatin has been associated with improvements in cardiac
function in a number of small controlled[67,69,90] and uncon-
trolled[68,88,91,92] studies of up to 12 months’ duration in patients
with hyperlipidemia, type 2 diabetes, heart disease, or heart failure
and in smokers. In patients with stable heart disease and serum
total cholesterol levels ‡220mg/dL, pitavastatin was associated
with a significant decrease in plasma brain natriuretic peptide
levels (65.0 vs 83.1 pg/mL; p< 0.05) and a significant increase in
echocardiographically assessed E/A wave velocity ratio (0.790 vs
0.741; p< 0.05) frombaseline,whereas no significant changeswere
seen in controls.[92] A significant increase in left ventricular ejec-
tion fraction (42% vs 48%; p= 0.002) and decrease in left ventri-
cular end-systolic volume (43 vs 40mm3; p< 0.001) from baseline
was seen in patients with ischemic or non-ischemic heart disease
treated with pitavastatin for a mean of 7.5 months.[91] In this
study, left ventricular end-diastolic dimension and E/A wave
velocity ratio did not alter significantly from baseline.
Pitavastatin improved arterial stiffness in two studies.[67,68]
In patients with hypercholesterolemia and preserved left ven-
tricular ejection fraction, pitavastatin was associated with re-
duced carotid arterial stiffness and improved ventricular
systolic and diastolic function compared with no statin.[67] At
endpoint, stiffness of the common carotid artery1 was signif-
icantly lower in patients receiving pitavastatin (stiffness b of 4.1
vs 5.6; p< 0.05), whereas this parameter did not alter significantly
in controls (5.1 vs 5.0). In an uncontrolled study, pitavastatin
improved arterial stiffness in atherosclerotic patients, as well as
reducing elevated PTX3 levels.[68] Pitavastatin produced short-
term improvements in endothelial function in two studies.[69,90]
Flow-mediated dilation was significantly greater in patients with
hypercholesterolemia treated with pitavastatin 2mg daily com-
pared with atorvastatin 10mg daily recipients (11.5% vs 8.6%;
p< 0.001).[69] Moreover, pitavastatin was associated with the re-
storation of endothelial function in chronic smokers.[90]
A study in 45 patients with type 2 diabetes showed pita-
vastatin to be associated with a significant reduction in cardio-
ankle vascular index, as well as significant reductions from
baseline in 8-OHdG and serum MDA LDL.[88]
4.4 Effect on Renal Function
Pitavastatin reduced clinical markers of CKD in small
studies in patients with non-diabetic CKD, with or without
1 Evaluated by M-mode ultrasonography and determined by the stiffness index, namely, stiffness b. Stiffness b = ln(SBP/DBP)/[(Ds-Dd)/Dd]
where Ds and Dd are the end-systolic and end-diastolic diameters of the common carotid artery, respectively, and SBP and DBP are the systolic
and diastolic BP, respectively. Stiffness bs are expressed as means of both common carotid artery measurements.
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hyperlipidemia, or early diabetic nephropathy.[81,89,93] In
two studies, pitavastatin 1mg daily administered for 6 and
12 months was associated with significant reductions in urinary
liver-type fatty acid-binding protein (L-FABP) levels and
urinary albumin excretion.[89,93] While pitavastatin did not
significantly reduce serum total cholesterol levels, significant
reductions from baseline in urinary albumin excretion (58 vs
110 mg/min; p < 0.01) and urinary L-FABP levels (8.8 vs
18.6 mg/g creatinine; p< 0.01) were seen in diabetic patients with
microalbuminuria (20–200 mg/min) receiving pitavastatin but
not in placebo recipients.[89] The effects of pitavastatin on renal
function in diabetic patients with macroalbuminuria and nor-
mal renal function or in patients with chronic renal failure who
were also recruited in this study were not reported.[89] In non-
diabetic patients with mild (stage I) CKD (mean serum crea-
tinine level 1.0mg/dL) and normal lipid levels, pitavastatin
1mg daily administered for 6 months reduced urinary pro-
tein excretion (1.0 vs 1.8 g/day; p< 0.05) and L-FABP levels
(28.0 vs 88.5 mg/g creatinine; p< 0.05).[93] Again, these changes
were independent of effects on lipid parameters; no signif-
icant changes in serum levels of total cholesterol or triglycerides
were seen.[93]
The addition of ezetimibe enhanced the effects of pit-
avastatin on markers of renal impairment in non-diabetic
patients with stage I or II CKD.[81] Compared with pitavastatin
monotherapy, pitavastatin plus ezetimibe produced significantly
greater reductions in proteinuria (from 1512 to 1042mg/day
with pitavastatin alone and from 1508 to 786mg/day with pit-
avastatin plus ezetimibe; p< 0.01 compared with pitavastatin
treatment alone) and urinary L-FABP levels (from 57.8 to
34.4 mg/g creatinine with pitavastatin alone and from 57.6 to
29.4 mg/g creatinine with pitavastatin plus ezetimibe; p< 0.01
compared with pitavastatin treatment alone), although no
significant changes in serum creatinine or GFR were reported
in either group.[81]Multiple stepwise regression analysis showed
that LDL cholesterol levels and urinary excretion of L-FABP
and 8-OHdG were independently related to proteinuria (with b
regression coefficients of 0.185 [p < 0.001], 0.312 [p = 0.001] and
0.557 [p < 0.001], respectively).[81]
Small improvements in renal function were seen in patients
with CKD receiving pitavastatin in a subgroup analysis of the
observational post-marketing LIVES study.[94] Patients with an
estimated GFR <60mL/min/1.73m2 (n = 958) experienced a
significant increase in mean GFR from baseline to 104 weeks
(47.8 vs 53.2mL/min/1.73m2; p < 0.001). The presence/absence
of proteinuria and change in serum HDL cholesterol level were
identified in a multivariate analysis as factors predicting the
increase in GFR.[94]
5. Tolerability
Pitavastatin was generally well tolerated in patients with
hyperlipidemia with or without type 2 diabetes in studies of
between 8 and 52 weeks’ duration.[47-55] Treatment-related
adverse events were generally mild to moderate in severity and
occurred in 5.3–16.7% of patients receiving pitavastatin 2 or
4mg daily[47,49-51] compared with 1.9–14.4% of patients re-
ceiving atorvastatin 10 or 20mg daily[47,49] and 8.2–23.5% of
patients receiving simvastatin 20mg or 40mg daily.[50,51] Figure 2
shows adverse events occurring with a frequency of ‡2% of
patients treated with pitavastatin 1–4mg/day in a pooled analysis
of short-term controlled studies of up 12 weeks’ duration.[10]
Other adverse events occurring in >2% of patients in clinical trials
include dizziness (2.9%), indigestion (2.2%), nasopharyngitis
(2.7–3.2%), and headache (2.2–3.4%).[47,49,50]
Treatment discontinuation due to adverse events occurred in
0.7–4.2% of patients receiving pitavastatin.[47,49-51]
Laboratory parameterswere closelymonitored during trials of
pitavastatin, but abnormalities were generally infrequent and not
clinically significant. Elevated plasma creatine kinase (CK) level
was the most commonly reported laboratory abnormality and
occurred in 3.8–4.4% of patients.[49,51,52] Although clinical sig-
nificance was reported in a heterogenous manner, themajority of
studies reported no large and/or symptomatic increases in CK
levels in patients receiving pitavastatin. Long-term follow-up of
one study reported increased CK levels in 5.8% and myalgia/
intercostal myalgia in 4.1% of patients after 52 weeks’ treatment
with pitavastatin 4mg daily.[60] However, of the 55 patients ex-
periencing myalgia, 34 patients were assessed as having mild and
21 as having moderate myalgia. Although elevated plasma CK
level was reported in 12 of these patients, the CK level did not
exceed ten times the upper limit of normal in anypatient and there
were no reports of rhabdomyolysis.[60] In the post-marketing
LIVES study, 10.4% of patients developed adverse drug re-
actions, with the majority being mild in severity.[61] The only
adverse event occurring in ‡2% of patients was an increase in CK
levels (2.74%). Six of the 19 925 patients in the LIVES study
evaluated for safety developed myopathy and only one patient
developed rhabdomyolysis that fulfilled diagnostic criteria.[61]
Elevated liver enzymes were reported in some patients receiving
pitavastatin in several studies, but these elevations were generally
mild and occurred in small numbers of patients.[49-54]
6. Discussion
Pitavastatin is a new addition to the statin family; it potently
and consistently exerts favorable effects on lipid parameters,
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produces additional effects independent of lipid reduction, is
effective and well tolerated in patients with co-morbid con-
ditions, and has a favorable pharmacokinetic profile.
After absorption, pitavastatin is taken up into the liver by
OATP2 and undergoes minimal metabolism by CYP en-
zymes.[95,96] It, therefore, has a low propensity for drug-drug
interactions with agents metabolized by CYP and grapefruit
juice, a CYP3A4 substrate.[35,36,95,96] In contrast, atorvastatin,
which is metabolized by CYP3A4, has an 83% greater exposure
in the presence of grapefruit juice[35] and a high propensity for
drug-drug interactions with other drugs metabolized by this
CYP isoenzyme.[95] This is important in patients treated with
statins that are likely to be receiving a number of other agents
for the treatment of co-morbidities.
Pitavastatin 2mg and 4mg daily reduces elevated total
cholesterol, LDL cholesterol, non-HDL cholesterol, and tri-
glyceride levels from baseline in adult patients with primary
hypercholesterolemia, including heterozygous familial hyper-
cholesterolemia and mixed dyslipidemia, where the response
to diet and other non-pharmacological measures is inade-
quate.[47-55] Reductions from baseline in total, LDL, and
non-HDL cholesterol levels of 21–32%, 30–45%, and 35–41%,
respectively, were seen in clinical trials, showing a potent lipid-
lowering effect.[47-55] The proportion of patients achieving
target LDL cholesterol levels reached as high as 94%. Potent
reductions in the serum level of triglycerides of 10–30% were
also seen. Pitavastatin was associated with a consistent trend
towards increased serum HDL-cholesterol levels of between
2.6% and 6.2%, and in two studies this increase was statistically
significant.[48,54] Pitavastatin was also associated with favor-
able effects on a number of other lipid parameters, including
increases in levels of ApoAI and ApoAII and decreases in Apo
B, Apo CII, Apo CIII, and Apo E levels.[47-55] Apo AI is an
essential component of the HDL particle and pitavastatin
promotes Apo AI production at lower concentrations than
atorvastatin in vitro.[16] Moreover, pitavastatin is more potent
than atorvastatin in stimulating lipoprotein lipase (LPL), which
may also increase HDL levels.[97] The combination of a potent
decrease in total and LDL cholesterol and increases in HDL
cholesterol suggest that pitavastatin may produce substantial
cardiovascular protection.
The favorable effects on lipid parameters of pitavastatin
were at least as good as currently prescribed statins. Clinical
trials show the lipid-lowering effects of pitavastatin to be sim-
ilar to the potent agent atorvastatin.[47,49,53-55] Moreover, pita-


















Back pain Constipation Diarrhea
Pitavastatin 1 mg daily
Pitavastatin 2 mg daily
Pitavastatin 4 mg daily
Placebo
Myalgia Pain in extremity
Fig. 2. Pooled results showing adverse events reported in ‡2% of patients and reported at a greater or equal rate than placebo in patients treated with
pitavastatin 1, 2, or 4mg daily or placebo in studies of up to 12 weeks’ duration.[10]
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profile than pravastatin and simvastatin in clinical trials.[50-52]
Taken together, these results make pitavastatin an attractive
therapeutic option in patients with primary hyperlipidemia or
mixed dyslipidemia who have not responded to diet or other
non-pharmacological measures.
Pitavastatin is effective in patients with type 2 diabetes or
glucose intolerance and does not worsen markers of glucose
intolerance, such as fasting blood glucose levels or HbA1c. In
diabetic patients, pitavastatin produced reductions in the levels
of total, LDL, and non-HDL cholesterol of 12–27%, 18–41%,
and 31%, respectively.[70-78] In addition, 6–29% reductions in
serum triglyceride levels were seen.[71,73-78] Pitavastatin pro-
duced significantly greater reductions in LDL cholesterol levels
versus atorvastatin in a small subset of patients with metabolic
syndrome in one study.[54] The mechanism by which pit-
avastatin demonstrated a better improvement in lipid para-
meters compared with atorvastatin is unclear. LPL expression
in 3T3-L1 preadipocytes is increased by pitavastatin in vitro.[97]
LPL activity is often suppressed in the presence of insulin re-
sistance but is crucial in very low-density lipoprotein and
remnant lipoprotein metabolism.[98] Pitavastatin also produced
favorable lipid responses in elderly patients[80] and in a small
study in patients with CKD.[80] These attributes make pita-
vastatin a potential alternative to other statins in the treatment
of patients with hyperlipidemia and metabolic co-morbidities.
Pitavastatin exerts a number of beneficial effects in-
dependent of lipid lowering. The JAPAN-ACS study provided
good evidence that pitavastatin improves atherosclerosis and
showed that it was non-inferior to atorvastatin at reducing
plaque volume in patients with ACS undergoing PCI.[84] A
number of small studies have demonstrated favorable effects
with pitavastatin, including beneficial effects on cardiovascular
function,[67-69,88,90-92] and reductions of markers of CKD.[81,89,93]
A number of exploratory analyses have shown pitavastatin to be
associated with reductions in serum levels of markers of in-
flammation and oxidative stress, suggesting that the agent may
have beneficial effects on the inflammatory changes occurring in
the arterial wall.[48-50,59,60,65,66,68,72,73,81,84,86-89] Taken together,
these results suggest that, in addition to contributing to a re-
duction in atherosclerosis, pitavastatin may have beneficial ef-
fects on cardiovascular risk in patients with hyperlipidemia with
or without co-morbid metabolic conditions.
Pitavastatin is generally well tolerated and the majority of
adverse events are mild to moderate in severity.[47-55] Like most
statins, pitavastatin has been associated with rare cases of
myopathy and rhabdomyolysis, and these have been the focus
of safety analyses in clinical trials and post-marketing surveil-
lance studies. While an elevated plasma CK level was seen in up
to 5% of patients treated with pitavastatin,[49,51,52] the number
of cases of myopathy or rhabdomyolysis fulfilling diagnostic
criteria was extremely low.[61]
The majority of clinical studies were in Asian populations
and clinical data in European populations and other ethnic
groups are lacking. Application of these study results to a more
heterogenous population in Europe or the US should, there-
fore, be done with caution until further studies are available.
7. Conclusion
Pitavastatin potently and consistently reduced the levels of
total cholesterol and LDL cholesterol in clinical trials, and was
consistently associated with a trend towards increased HDL
cholesterol levels. These favorable effects on lipid parameters
are generally similar to those observed with atorvastatin and
tend to be somewhat greater than the other statins, such as
simvastatin. These benefits are also evident in special patient
populations, such as patients with type 2 diabetes, CKD, and
the elderly.
Aside from its beneficial effects on lipid profiles, pitavastatin
may have additional favorable effects that are independent of
its cholesterol-lowering properties and may contribute towards
decreasing patients’ risk of cardiovascular morbidity and
mortality. These effects include regression of atherosclerosis,
improved cardiovascular and endothelial function, and re-
duced levels of inflammatory markers, such as hs-CRP.
Pitavastatin demonstrates good tolerability in clinical trials
and in a large post-marketing surveillance study, has little
deleterious effect on glucose tolerance, and exhibits a low in-
cidence of musculoskeletal adverse events.
Pitavastatin has a favorable pharmacokinetic profile. It is
less likely to interact with drugs metabolized by CYP enzymes
and this is particularly important in patients with multiple
pathologies, such as type 2 diabetes and cardiovascular and
renal disease, who often require polypharmacy. Future studies
are needed to reconfirm the efficacy of pitavastatin in non-
Asian populations and to define the effects of pitavastatin on
reducing mortality and morbidity in patients at high risk of
cardiovascular events.
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